The 5'-triphosphates of 1-(2'-deoxy-2'-fluoro-j-D-arabinofuranosyl)-5-methyluracil, 1-(2'-deoxy-2'-fluoro-P-D-arabinofuranosyl)-5-iodocytosine, 1-(2'-deoxy-2'-fluoro-p-D-arabinofuranosyl)-5-methylcytosine, 94(2-hydroxyethoxy)methyl]guanine, and 9-(1,3-dihydroxy-2-propoxymethyl)guanine had lower Ki values for Epstein-Barr virus DNA polymerase than has been reported elsewhere for host DNA polymerase. Inhibition of DNA elongation by these analogs ranged from moderate to strong, suggesting that preferential incorporation of these analogs into DNA by virus DNA polymerase may contribute to antiviral selectivity.
Epstein-Barr virus (EBV), a member of the herpesvirus family, is recognized as an important human pathogen and is closely associated with certain human malignancies (10, 11, 15) . Thus, it would be useful to develop selective anti-EBV compounds. The approach taken in this laboratory is to design compounds based on the unique properties of virusspecified enzymes (2, 5) . EBV is known to induce its own specific DNA polymerase (8, 14, 18) . The properties of this EBV-specified enzyme are in many ways similar to the properties of herpes simplex virus (HSV) DNA polymerase, which are different from those of human DNA polymerases (1, 8, 9, 14, 19) . It is logical, therefore, to consider EBV DNA polymerase as a target for developing anti-EBV agents.
Acyclovir (ACV) has been shown to have potent anti-EBV activity, although the action was readily reversible upon removal of ACV from the culture medium (6, 7) . The action of ACV against EBV replication was suggested to be due to inhibition of EBV DNA polymerase by ACV-triphosphate (ACVTP), which is a potent inhibitor that competes with dGTP for binding to EBV DNA polymerase (7) . In addition to the ability to be preferentially phosphorylated by HSV-specified thymidine kinase, several triphosphates of anti-HSV nucleoside analogs have higher binding affinities to HSV type 1 (HSV-1) and HSV-2 DNA polymerase than to human enzymes (3, 9, 12, 13) , which could contribute to their selectivity of action against HSV. Based on the similarity of herpesvirus DNA polymerases, it is conceivable that some of these anti-HSV nucleoside analogs also have a selective anti-EBV activity, possibly caused by preferential interaction of EBV DNA polymerase with their triphosphate metabolites. Thus, we examined the effect of several anti-HSV nucleoside analogs against EBV replication in culture.
, and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) are potent inhibitors of EBV replication at noncytotoxic concentrations, and their antiviral activity is quite irreversible (4, 16) . Since the anti-EBV activity of these nucleoside analogs could be due to their preferential interaction with EBV DNA polymerase once they are phosphorylated, the effects of FMAUTP, FIACTP, the 5'-triphosphate of 1-(2'-deoxy-2'-fluoro-,-D-arabinofuranosyl)-5-methylcytosine (FMACTP), DHPGTP, and ACVTP * Corresponding author.
on EBV DNA polymerase were examined. The enzyme used was highly purified according to procedures described previously by us to a specific activity of more than 4.0 x 105 U/mg of protein (20) . The preparations of FMAUTP, FIACTP, FMACTP, DHPGTP, and ACVTP were previously published (13, 19 (9, 13) . These results suggest that the mode of action of both compounds with EBV DNA polymerase is the same as with HSV DNA polymerase. Both ACVTP and DHPGTP can be incorporated into the DNA template; however, the DHPG- a Analog dNTPs were prepared as described previously (13, 19) . Km values were determined from Lineweaver-Burk plots with five different concentrations of variable dNTP. Ki values were determined by replotting LineweaverBurk plots which employed three drug concentrations. All compounds were assayed concurrently against radioactive competing substrates in amounts 0.3 to 2.0 times the Km. Noncompeting dNTPs were present at 100 ,uM each. The assay conditions were as described previously (9) terminated DNA is poorly elongated, whereas the ACV-terminated DNA is not elongated at all. In addition, ACV-or DHPG-terminated DNA could interfere with the DNA polymerase action by competing with unsubstituted DNA templates. Obtaining final proof of this hypothesis will require an analog with high radiospecificity. In summary, our studies suggest that these analogs are preferentially incorporated into DNA by EBV DNA polymerase, which could be part of the mechanism responsible for their selective anti-EBV action. Since ACV was incorporated only at the termini of growing DNA chains, whereas FMAU, FIAC, FMAC, and DHPG were incorporated in both terminal and internal positions, this could be part of the reason why the anti-EBV actions of FMAU, FIAC, and DHPG are less reversible than that of ACV (4, 17). 
